All In Biotech

Drug Trial Radar · NCT05289661

Descemet Endothelial Thickness Comparison Trial I

Descemet Endothelial Thickness Comparison Trials (DETECT I & II)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Actual

Start

Jul 15, 2022

Primary completion

Nov 30, 2026

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Oregon Health and Science University; University of California, San Francisco; University of California, Davis; Case Western Reserve University; Dartmouth-Hitchcock Medical Center; University of Pennsylvania; University of Miami; Wills Eye Hospital
First posted
Mar 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on endothelial cell loss.

Conditions

  • Fuchs

Interventions

  • Topical RipasudilDrug

    To determine the effect of rho-kinase inhibitors on endothelial cell loss

  • Topical PlaceboDrug

    topical Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best spectacle-corrected visual acuity (BSCVA)Time frame: 12 months
  2. Endothelial cell lossTime frame: 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

  • University of California Davis

    Sacramento, California

  • University of Miami

    Palm Beach Gardens, Florida

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Oregon Health & Science University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Wills Eye Hospital

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.